Baxter International Medical Device Company Intelligence Report

Date: January 30, 2013
Pages: 39
US$ 515.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Baxter International Medical Device Company Intelligence Report
Baxter International Inc develops, manufactures and markets products for the treatment of haemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The company applies a combination of expertise in medical devices, pharmaceuticals and biotechnology.

Prior to 2011, Baxter operated under three business segments: BioScience, Medication Delivery and Renal. As of 1st January 2011, the company combined its Medication Delivery and Renal businesses into a single global business unit to form the Medical Products business.

Medical Products – manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, prefilled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anaesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease. The business manufactures solutions and other products for peritoneal dialysis (PD), a home-based therapy, and distributes products for haemodialysis.

BioScience – processes recombinant and plasma-based proteins to treat haemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. In March 2010, Baxter acquired ApaTech, which provided the company with immediate entry into the emerging bone fusion field.

This profile primarily concentrates on Baxter’s medical device activities.

In December of 2012, Baxter entered into a definitive agreement to acquire privately-held Gambro, for total consideration approximately US$4.0 billion. Gambro is a global medical technology company focused on developing, manufacturing and supplying dialysis products and therapies for patients with acute or chronic kidney disease. The acquisition will give Baxter a comprehensive dialysis product portfolio, complementing its existing home dialysis offerings.

It is believed that the transaction will provide a number of long-term growth opportunities for Baxter worldwide. With a broad and complementary dialysis product portfolio, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive footprint. Baxter can also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis business. In addition, Baxter will also build upon its pipeline of investigational home haemodialysis and automated PD systems with the addition of Gambro's monitors, dialysers, devices and dialysis systems.

In January 2012, Baxter rejected an unsolicited mini-tender offer by TRC Capital Corporation to purchase up to two million shares, or approximately 0.35%, of Baxter’s outstanding common stock at a price of US$46.10 per share in cash. The offer price was 4.67% below the US$48.36 closing price of Baxter’s common stock on 15th December 2011, the day prior to the offer.

Baxter has approximately 48,500 employees and conducts business in over 100 countries. In 2011, the company reported revenues of US$13.89 billion, of which approximately 59% were generated outside of the US. Baxter maintains manufacturing and distribution facilities in a number of locations in the US, Europe, Canada, Asia-Pacific and Latin America.

In Business Monitor International’s list of top ten US medical device manufacturers 2006-2011, Baxter was ranked in fourth position, behind Johnson & Johnson, GE and Medtronic.

This company report provides

  • Key contact information
  • Introduction to the company and its current activities
  • Summary of its financial performance
  • Who are the company’s major competitors?
  • Key recent events in an “at a glance” format
Financial Review
  • Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
  • Table providing in-depth five-year financial analysis
  • Employee data, including breakdown by company division and geographic location
Strategic Focus

Investigates the company’s aims and its areas of focus


Core product areas, key brands, product approvals and launches

Research and Development
  • How much has been invested in R&D?
  • Where is the research based?
  • What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
  • Identifying the company’s manufacturing locations
  • Sales and marketing facilities
  • With whom has the company reached agreements and what do they involve?
  • Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments


Key Corporate Events


Product Approvals & Launches
Other Developments
Espicom View


2011 Financial Results
  Medical Products Division
    Global Injectables
    IV Therapies
    Infusion Systems
  BioScience Division
    Plasma Proteins
    Antibody Therapy
    Regenerative Medicine
Five-Year Financial Data


Medical Products
  Medication Delivery
    Peritoneal Dialysis (PD) Solutions
    Automated Peritoneal Dialysis (APD) and Continuous Ambulatory Peritoneal Dialysis (CAPD) Products �17
    HD Products
    Regenerative Medicine


R&D Focus
R&D Expenditure
Trials and Studies
Research Agreements
  MaRS Innovation
  Kuros Biosurgery



AWAK Technologies
Angiotech Pharmaceuticals
Innocoll Pharmaceuticals
DEKA Research & Development and HHD
Intercytex (now Healthpoint)
Spinal Restoration


Gambro AB
SIGMA International
Synovis Life Technologies
Assets Relating to Edwards Lifesciences’ CRRT Product Line
Willow Healthcare Services
MAAS Medical


AWAK Technologies


Transfusion Therapies Business
Disposable Airway Management Business
Renal Service Businesses


Guangzhou Baxter Qiaoguang Healthcare
Eczacibasi Baxter Hospital Supply Products Company


  Peritoneal Dialysis Litigation
  Haemodialysis Litigation



Recent Key Events
Baxter - Annual Financial Results, 2007-2011
Baxter - Annual Net Sales by Business Segment and Geographic Area, 2009-2011
Baxter Medical Products Division - Annual Net Sales, 2009-2011
Baxter BioScience Division - Annual Net Sales, 2009-2011
Baxter - Five-Year Financial Summary
Baxter – Summary of Medical Products
Market Position of Major Renal Product Groups, 2011
Baxter – Summary of Renal Products
Baxter - Annual R&D Expenses, 2007-2011
Baxter’s Principal Manufacturing Facilities by Segment, December 2011
Agreements Summary
Mergers and Acquisitions Summary
Divestitures Summary


Baxter - Annual Net Sales and Operating Income, 2007-2011
Baxter - Annual Sales by Business Sector, 2009-2011
Baxter - Annual Sales by Geographic Area, 2009-2011
Baxter Medical Products Division - Annual Net Sales by Product Sector, 2009-2011
Baxter BioScience Division Sales by Product Sector, 2009-2011
Baxter - 2011 Sales of Medical Products
Baxter – 2009-2011 Renal Product Sales
Baxter – 2011 BioScience Product Sales
Baxter – Summary of BioSurgery Products
Skip to top

Terumo Medical Device Company Intelligence Report US$ 515.00 Feb, 2013 · 41 pages
Sorin Medical Device Company Intelligence Report US$ 515.00 Jun, 2012 · 42 pages
Smith Medical Device Company Intelligence Report US$ 515.00 Mar, 2013 · 40 pages
Fresenius Medical Device Company Intelligence Report US$ 515.00 Apr, 2013 · 42 pages

Ask Your Question

Baxter International Medical Device Company Intelligence Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: